• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ProMIS Neurosciences Inc. (Amendment)

    2/5/24 9:10:36 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMN alert in real time by email
    SC 13G/A 1 zk2430877.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G

    (Amendment No.1)*

    ProMIS Neurosciences Inc.
    (Name of Issuer)

    Common Shares, no par value per share
     (Title of Class of Securities)

    74346M406
    (CUSIP Number)

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No. 74346M406
    13G
    Page 2 of 10 Pages
    1
    NAME OF REPORTING PERSONS
     
    Sphera Funds Management Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    --
    6
    SHARED VOTING POWER
     
    1,892,474 (*)
    7
    SOLE DISPOSITIVE POWER
     
    --
    8
    SHARED DISPOSITIVE POWER
     
    1,892,474 (*)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,892,474 (*)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    9.99% (*) (**)
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    CO

    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) Based on 18,885,254 Common Shares outstanding as of November 10, 2023 (as provided by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 14, 2023) and 58,432 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.

    2


    CUSIP No. 74346M406
    13G
    Page 3 of 10 Pages
    1
    NAME OF REPORTING PERSONS
     
    Sphera Global Healthcare GP Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    --
    6
    SHARED VOTING POWER
     
    1,892,474 (*)
    7
    SOLE DISPOSITIVE POWER
     
    --
    8
    SHARED DISPOSITIVE POWER
     
    1,892,474 (*)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,892,474 (*)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
     ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    9.99% (*) (**)
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    CO

    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) Based on 18,885,254 Common Shares outstanding as of November 10, 2023 (as provided by the Issuer in its Form 10-Q filed with the SEC on November 14, 2023) and 58,432 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.

    3


    CUSIP No. 74346M406
    13G
    Page 4 of 10 Pages
    1
    NAME OF REPORTING PERSONS
     
    Sphera Global Healthcare Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    --
    6
    SHARED VOTING POWER
     
     1,892,474 (*)
    7
    SOLE DISPOSITIVE POWER
     
    --
    8
    SHARED DISPOSITIVE POWER
     
     1,892,474 (*)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     1,892,474 (*)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    9.99% (*) (**)
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    PN

    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) Based on 18,885,254 Common Shares outstanding as of November 10, 2023 (as provided by the Issuer in its Form 10-Q filed with the SEC on November 14, 2023) and 58,432 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.

    4


    Item 1.       (a)
    Name of Issuer:

    ProMIS Neurosciences Inc.

                       (b)
    Address of Issuer's Principal Executive Offices:

    Suite 200, 1920 Yonge Street, Toronto, Ontario M4S 3E2

    Item 2.       (a)
    Name of Person Filing:

    Sphera Funds Management Ltd.

    Sphera Global Healthcare GP Ltd.

    Sphera Global Healthcare Management LP


    (b)
    Address of Principal Business Office:

    Sphera Funds Management Ltd. – 4 Itzak Sade, Building A, 29th Floor, Tel Aviv 6777504, Israel

    Sphera Global Healthcare GP Ltd. – 4 Itzak Sade, Building A, 29th Floor, Tel Aviv 6777504, Israel

    Sphera Global Healthcare Management LP – 4 Itzak Sade, Building A, 29th Floor, Tel Aviv 6777504, Israel


    (c)
    Citizenship:

    Sphera Funds Management Ltd. – Israel

    Sphera Global Healthcare GP Ltd. – Israel

    Sphera Global Healthcare Management LP – Israel


    (d)
    Title of Class of Securities:

    Common Shares, no par value per share


    (e)
    CUSIP Number:

    74346M406

    Item 3.
    Not applicable.

    Item 4.
    Ownership:


    (a)
    Amount beneficially owned:

    See row 9 of cover page of each reporting person.
    5


    The securities reported herein by Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP are beneficially owned as follows:


    •
    372,340 Common Shares representing a total of 1.97% of the total Common Shares outstanding are held directly by Sphera Global Healthcare Master Fund, which has delegated its investment management authority to Sphera Global Healthcare Management LP (the "Management Company").
     

    •
    1,461,702 Common Shares and 58,432 pre-funded warrants, with each warrant currently exercisable into one Common Share, together representing a total of 8.02% of the total Common Shares outstanding, are held directly by Sphera Biotech Master Fund, L.P., which has delegated its investment management authority to the Management Company.

    The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd., the shares of which are owned 90% by Sphera Funds Management Ltd.

    This Statement shall not be construed as an admission by any of the Reporting Persons that it is the beneficial owner of any of the securities covered by this Statement, and each Reporting Person disclaims beneficial ownership of any such securities. In addition, the Reporting Persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the Reporting Persons and other entities named in this Schedule 13G disclaims the existence of any such group.


    (b)
    Percent of class:

    See row 11 of cover page of each reporting person


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote:

    See row 5 of cover page of each reporting person


    (ii)
    Shared power to vote or to direct the vote:

    See row 6 of cover page of each reporting person and note in Item 4(a) above


    (iii)
    Sole power to dispose or to direct the disposition of:

    See row 7 of cover page of each reporting person


    (iv)
    Shared power to dispose or to direct the disposition of:

    See row 8 of cover page of each reporting person and note in Item 4(a) above

    6


    Item 5.
    Ownership of Five Percent or Less of a Class:

    Not applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another:

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group:

    Not applicable.

    Item 9.
    Notice of Dissolution of Group:

    Not applicable.
    7


    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    8

     SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    February 4, 2024
     
     
    Sphera Funds Management Ltd.

    /s/ Adi Hanetz
    By: Adi Hanetz
    Title: General Counsel
       
     
    Sphera Global Healthcare GP Ltd.

    /s/ Adi Hanetz
    By: Adi Hanetz
    Title: General Counsel
       
     
    Sphera Global Healthcare Management LP

    /s/ Adi Hanetz
    By: Adi Hanetz
    Title: General Counsel

    9


    EXHIBIT NO.
    DESCRIPTION
     
    Exhibit 1
    Joint Filing Agreement by and among the Reporting Persons (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on August 30, 2023)
     

    10
    Get the next $PMN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Jeremy M. Sclar 2012 Irrevocable Family Trust converted options into 2,093,022 shares, increasing direct ownership by 129% to 3,710,459 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    9/30/25 4:17:04 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Jeremy M. Sclar 2012 Irrevocable Family Trust claimed ownership of 1,617,437 shares (SEC Form 3)

    3 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    9/30/25 4:15:38 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Warma Neil K

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    9/24/25 8:58:33 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    SEC Filings

    View All

    ProMIS Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)

    9/30/25 4:15:13 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by ProMIS Neurosciences Inc.

    PRE 14A - ProMIS Neurosciences Inc. (0001374339) (Filer)

    9/23/25 5:14:23 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by ProMIS Neurosciences Inc.

    EFFECT - ProMIS Neurosciences Inc. (0001374339) (Filer)

    9/11/25 12:15:27 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics

    USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 18, 2025 /PRNewswire/ -- USA News Group News Commentary –Today, Americans over 65 command $22,356 in annual healthcare spending per person versus just $4,217 for children[1], driving unprecedented investment in longevity solutions as populations worldwide confront global demographics where those aged 60+ will surge from 900 million in 2015 to 2 billion by 2050[2]. These macro forces position Avant Technologies, Inc. (OTCQB:AVAI), HCW Biologics Inc. (NASDAQ:HCWB), Solid Biosciences Inc. (NASDAQ:SLDB), ProMIS Neuorsciences, Inc. (NASDAQ:PMN), and uniQure N.V. (NASDAQ:QURE).

    9/18/25 9:10:00 AM ET
    $HCWB
    $PMN
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

    Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026. Cambridge, Massachusetts, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that the independent Data and Safety Monitoring Board (DSMB) for its ongoing PRECISE-AD Phase 1b clinical tri

    9/3/25 7:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

    U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program's potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer's Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date Strengthened Financial Position with $21.6 Million in Gross Proceeds Raised in July 2025 Cambridge, Massachusetts, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral scleros

    8/13/25 7:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Leadership Updates

    Live Leadership Updates

    View All

    $PMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $PMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-

    5/14/24 4:01:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve

    4/1/24 4:15:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences, Inc. Announces Leadership Transition

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced a strategic leadership change. The Company's Board of Directors appointed Neil Warma, a highly-qualified biotechnology industry executive and ProMIS Board member, as interim Chief Executive Officer to succeed Gail Farfel, Ph.D., who has stepped down to pursue other opportunities. Mr. Warma's appoint

    1/3/24 7:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Cashman Neil bought $14,595 worth of shares (15,000 units at $0.97) (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    2/12/25 5:21:35 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Shafmaster Madge K. bought $255,750 worth of shares (200,000 units at $1.28), increasing direct ownership by 2,400% to 208,333 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    9/24/24 6:56:35 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gordon Michael S bought $116,880 worth of shares (93,223 units at $1.25) (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    9/18/24 4:15:05 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 4:56:13 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ProMIS Neurosciences Inc.

    SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 3:36:04 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/6/24 4:15:57 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care